Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic) (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EPS (Basic) data on record, last reported at -$0.46 in Q4 2025.

  • For Q4 2025, EPS (Basic) fell 58.62% year-over-year to -$0.46; the TTM value through Dec 2025 reached $0.18, up 111.25%, while the annual FY2025 figure was $0.18, 111.25% up from the prior year.
  • EPS (Basic) reached -$0.46 in Q4 2025 per APLS's latest filing, down from $1.71 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.71 in Q3 2025 and bottomed at -$2.72 in Q2 2021.
  • Average EPS (Basic) over 5 years is -$1.04, with a median of -$1.1 recorded in 2023.
  • Peak YoY movement for EPS (Basic): tumbled 244.34% in 2021, then soared 463.83% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$1.53 in 2021, then increased by 0.65% to -$1.52 in 2022, then skyrocketed by 53.95% to -$0.7 in 2023, then surged by 58.57% to -$0.29 in 2024, then plummeted by 58.62% to -$0.46 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.46 in Q4 2025, $1.71 in Q3 2025, and -$0.33 in Q2 2025.